Symphogen A/S - Product Pipeline Review - 2015

Date: July 31, 2015
Pages: 42
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S09BD8032E9EN
Leaflet:

Download PDF Leaflet

Symphogen A/S - Product Pipeline Review - 2015

SUMMARY

Global Markets Direct’s, ‘Symphogen A/S - Product Pipeline Review - 2015’, provides an overview of the Symphogen A/S’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Symphogen A/S’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides brief overview of Symphogen A/S including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Symphogen A/S’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Symphogen A/S’s pipeline products
REASONS TO BUY
  • Evaluate Symphogen A/S’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Symphogen A/S in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Symphogen A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Symphogen A/S and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Symphogen A/S
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Symphogen A/S and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Symphogen A/S Snapshot
Symphogen A/S Overview
Key Information
Key Facts
Symphogen A/S - Research and Development Overview
Key Therapeutic Areas
Symphogen A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Symphogen A/S - Pipeline Products Glance
Symphogen A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Symphogen A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Symphogen A/S - Drug Profiles
futuximab
Product Description
Mechanism of Action
R&D Progress
Sym-002
Product Description
Mechanism of Action
R&D Progress
Sym-006
Product Description
Mechanism of Action
R&D Progress
Sym-009
Product Description
Mechanism of Action
R&D Progress
Sym-013
Product Description
Mechanism of Action
R&D Progress
SYM-015
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies 1 for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies 2 for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Antagonize FGFR for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit PD-1 for Cancer
Product Description
Mechanism of Action
R&D Progress
Sym-008
Product Description
Mechanism of Action
R&D Progress
Sym-012
Product Description
Mechanism of Action
R&D Progress
Sym-014
Product Description
Mechanism of Action
R&D Progress
Symphogen A/S - Pipeline Analysis
Symphogen A/S - Pipeline Products by Target
Symphogen A/S - Pipeline Products by Route of Administration
Symphogen A/S - Pipeline Products by Molecule Type
Symphogen A/S - Pipeline Products by Mechanism of Action
Symphogen A/S - Recent Pipeline Updates
Symphogen A/S - Dormant Projects
Symphogen A/S - Company Statement
Symphogen A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Symphogen A/S, Key Information
Symphogen A/S, Key Facts
Symphogen A/S - Pipeline by Indication, 2015
Symphogen A/S - Pipeline by Stage of Development, 2015
Symphogen A/S - Monotherapy Products in Pipeline, 2015
Symphogen A/S - Phase II, 2015
Symphogen A/S - Phase I, 2015
Symphogen A/S - Preclinical, 2015
Symphogen A/S - Discovery, 2015
Symphogen A/S - Pipeline by Target, 2015
Symphogen A/S - Pipeline by Route of Administration, 2015
Symphogen A/S - Pipeline by Molecule Type, 2015
Symphogen A/S - Pipeline Products by Mechanism of Action, 2015
Symphogen A/S - Recent Pipeline Updates, 2015
Symphogen A/S - Dormant Developmental Projects,2015
Symphogen A/S, Subsidiaries

LIST OF FIGURES

Symphogen A/S - Pipeline by Top 10 Indication, 2015
Symphogen A/S - Pipeline by Stage of Development, 2015
Symphogen A/S - Monotherapy Products in Pipeline, 2015
Symphogen A/S - Pipeline by Top 10 Target, 2015
Symphogen A/S - Pipeline by Top 10 Route of Administration, 2015
Symphogen A/S - Pipeline by Top 10 Molecule Type, 2015
Symphogen A/S - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Symphogen A/S - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: